Theravance Biopharma Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Theravance Biopharma Inc Company

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.

Theravance Biopharma Inc Info



Ticker SymbolTBPH

Company nameTheravance Biopharma Inc

IPO dateMay 16, 2014

CEOMr. Rick E. Winningham

Number of employees97

Security typeOrdinary Share

Fiscal year-endMay 16

AddressUgland House, South Church Street

CityGEORGE TOWN

Stock exchangeNASDAQ Global Market Consolidated

CountryCayman Islands

Postal codeKY1-1104

Phone16508086000

Websitehttps://www.theravance.com/

Ticker SymbolTBPH

IPO dateMay 16, 2014

CEOMr. Rick E. Winningham

Company Executives of Theravance Biopharma Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Rick E. Winningham

Chief Executive Officer, Director

1.29M

-1.18%

Dr. Aine Miller

Senior Vice President - Development and Head of Ireland Office

208.00K

-3.25%

Mr. Brett A. Grimaud

Senior Vice President, General Counsel, Secretary

150.40K

-6.10%

Mr. Aziz Sawaf

Chief Financial Officer, Senior Vice President

132.77K

-6.59%

Mr. Eran Broshy

Independent Director

91.20K

+13.22%

Mr. Donal O'Connor

Independent Director

74.20K

+16.76%

Dr. Deepika R. Pakianathan, Ph.D.

Independent Director

58.06K

+22.46%

Ms. Susannah Gray

Independent Chairman of the Board

42.14K

+33.82%

Mr. Jeremy T. Grant

Independent Director

28.54K

+59.52%

Mr. Dean Jonathan (Dean) Mitchell

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Rick E. Winningham

Chief Executive Officer, Director

1.29M

-1.18%

Dr. Aine Miller

Senior Vice President - Development and Head of Ireland Office

208.00K

-3.25%

Mr. Brett A. Grimaud

Senior Vice President, General Counsel, Secretary

150.40K

-6.10%

Mr. Aziz Sawaf

Chief Financial Officer, Senior Vice President

132.77K

-6.59%

Mr. Eran Broshy

Independent Director

91.20K

+13.22%

Mr. Donal O'Connor

Independent Director

74.20K

+16.76%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

No Data

By RegionUSD

Name

Revenue

Proportion

U.S.

64.38M

0.00%

Europe

0.00

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Wed, Oct 8

Shareholders

Shareholder Types

Shareholders

Proportion

Madison Avenue Partners LP

18.89%

Weiss Asset Management

14.81%

Newtyn Management, LLC

9.83%

BlackRock Institutional Trust Company, N.A.

6.54%

Irenic Capital Management LP

5.48%

Other

44.45%

Shareholders

Proportion

Madison Avenue Partners LP

18.89%

Weiss Asset Management

14.81%

Newtyn Management, LLC

9.83%

BlackRock Institutional Trust Company, N.A.

6.54%

Irenic Capital Management LP

5.48%

Other

44.45%

Shareholder Types

Shareholders

Proportion

Hedge Fund

59.08%

Investment Advisor

17.40%

Investment Advisor/Hedge Fund

12.71%

Individual Investor

4.57%

Research Firm

3.78%

Pension Fund

0.28%

Bank and Trust

0.09%

Insurance Company

0.03%

Other

2.06%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

289

47.06M

93.45%

-4.43M

2025Q2

288

48.49M

96.98%

-9.87M

2025Q1

306

49.02M

97.92%

-10.33M

2024Q4

307

49.22M

100.10%

-11.44M

2024Q3

311

50.46M

103.15%

-9.84M

2024Q2

312

51.86M

106.61%

-21.43M

2024Q1

304

56.26M

115.67%

-11.52M

2023Q4

301

56.96M

111.33%

-13.16M

2023Q3

314

59.36M

109.50%

-14.46M

2023Q2

331

61.03M

103.70%

-24.91M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Madison Avenue Partners LP

9.51M

18.89%

--

Jun 30, 2025

Weiss Asset Management

7.46M

14.81%

--

Jun 30, 2025

Newtyn Management, LLC

4.95M

9.83%

+192.60K

+4.05%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.29M

6.54%

+259.25K

+8.54%

Jun 30, 2025

Irenic Capital Management LP

2.76M

5.48%

--

Jun 30, 2025

The Vanguard Group, Inc.

2.16M

4.28%

+76.97K

+3.70%

Jun 30, 2025

Park West Asset Management LLC

1.80M

3.57%

-5.16K

-0.29%

Jun 30, 2025

Winningham (Rick E)

1.29M

2.57%

-15.39K

-1.18%

Aug 20, 2025

Oasis Management Company Ltd.

1.12M

2.22%

--

Jun 30, 2025

State Street Investment Management (US)

1.04M

2.06%

-31.13K

-2.92%

Jun 30, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

Virtus LifeSci Biotech Products ETF

2.29%

Inspire Fidelis Multi Factor ETF

1.06%

Janus Henderson Small Cap Growth Alpha ETF

0.79%

Invesco NASDAQ Future Gen 200 ETF

0.51%

Global X Aging Population ETF

0.46%

ALPS Medical Breakthroughs ETF

0.44%

SPDR S&P Pharmaceuticals ETF

0.33%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.24%

iShares U.S. Pharmaceuticals ETF

0.2%

SPDR SSGA US Small Cap Low Volatility Index ETF

0.19%

Virtus LifeSci Biotech Products ETF

Proportion2.29%

Inspire Fidelis Multi Factor ETF

Proportion1.06%

Janus Henderson Small Cap Growth Alpha ETF

Proportion0.79%

Invesco NASDAQ Future Gen 200 ETF

Proportion0.51%

Global X Aging Population ETF

Proportion0.46%

ALPS Medical Breakthroughs ETF

Proportion0.44%

SPDR S&P Pharmaceuticals ETF

Proportion0.33%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion0.24%

iShares U.S. Pharmaceuticals ETF

Proportion0.2%

SPDR SSGA US Small Cap Low Volatility Index ETF

Proportion0.19%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data